MedPath

Nimustine

Generic Name
Nimustine
Drug Type
Small Molecule
Chemical Formula
C9H13ClN6O2
CAS Number
42471-28-3
Unique Ingredient Identifier
0S726V972K

Overview

Nimustine has been used in trials studying the treatment of Glioblastoma.

Background

Nimustine has been used in trials studying the treatment of Glioblastoma.

Indication

适用于脑瘤、肺癌、慢性白血病、恶性淋巴瘤、消化道癌。

Associated Conditions

No associated conditions information available.

Clinical Trials

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
Nimustine Hydrochloride for Injection
国药准字H20059251
化学药品
注射剂
7/18/2024
Nimustine Hydrochloride for Injection
国药准字H20046672
化学药品
注射剂
6/19/2020
Nimustine Hydrochloride for Injection
国药准字H20058694
化学药品
注射剂
3/3/2022
Nimustine Hydrochloride for Injection
国药准字H20046533
化学药品
注射剂
7/28/2020
Nimustine Hydrochloride for Injection
国药准字H20065314
化学药品
注射剂(冻干粉针剂)
1/28/2021
Nimustine Hydrochloride for Injection
国药准字H20059604
化学药品
注射剂
9/16/2023
Nimustine Hydrochloride for Injection
国药准字H20057157
化学药品
注射剂
7/13/2022
Nimustine Hydrochloride for Injection
国药准字H20053686
化学药品
注射剂
8/6/2024
Nimustine Hydrochloride for Injection
国药准字H20044292
化学药品
注射剂
5/22/2020

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.
© Copyright 2025. All Rights Reserved by MedPath